ReviewReported positiveLimited evidenceTier 4 · clinical
Drugs · Jun 2026 · regulatory approval summary
Relacorilantepithelial ovarian cancerfallopian tube cancerprimary peritoneal cancerpancreatic cancerprostate cancer Relacorilant is a non-steroidal, selective glucocorticoid receptor antagonist being developed for several solid tumours and Cushing syndrome. The article reports that relacorilant received its first approval in the USA on 25 March 2026 for use in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after 1-3 prior systemic regimens (at least one including bevacizumab). The article summarizes development milestones leading to this approval.
Studied with: nab-paclitaxel.
Key findings
- Relacorilant is a non-steroidal, selective glucocorticoid receptor II antagonist developed by Corcept Therapeutics.
- Relacorilant received first approval in the USA on 25 March 2026.
- Approval is for use in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens, at least one of which included bevacizumab.
- Relacorilant is being developed for various solid tumours including ovarian, fallopian tube, peritoneal, pancreatic and prostate cancers, as well as for Cushing syndrome.
- The article summarizes milestones in the development of relacorilant leading to this approval.
Limitations: Abstract provides no efficacy or safety outcome data or numeric results from trials.; No trial design, sample size, or methods are reported in the abstract.; This is an approval/summary article, not primary trial data.; Geographic scope limited to a USA approval; supporting evidence is not detailed in the abstract..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewReported positivePreclinical onlyTier 1 · lab
Molecular biology reports · May 2026 · narrative review
Genisteinbreast cancerovarian cancerprostate cancergliomaneuroblastomahepatocellular carcinomalung cancerbladder cancerosteosarcomarhabdomyosarcoma This is a narrative review of the biological activities and potential therapeutic roles of soy isoflavones (including genistein and daidzein). The authors summarize proposed anticancer mechanisms (estrogen receptor modulation, apoptosis, anti-angiogenesis, epigenetic effects, etc.) and report that in vitro and in vivo studies have shown promising results across a range of tumor types. They conclude that further research—especially studies combining isoflavones with established chemotherapeutics—is needed.
Studied with: chemotherapeutic agents.
Key findings
- Soy isoflavones (genistein, daidzein) have estrogenic and non-estrogenic activities including anti-inflammatory, antioxidant, and immunomodulatory effects.
- Proposed anticancer mechanisms include modulation of estrogen receptors, copper ion-dependent induction of cell death, promotion of apoptosis, inhibition of angiogenesis and metastasis, regulation of epigenetic processes, and effects on platelet function.
- Because of estrogen receptor interactions, isoflavones have been studied particularly in hormone-dependent cancers such as breast, ovarian, and prostate cancer.
- In vitro and in vivo studies have reported promising results in multiple malignancies (gliomas, neuroblastoma, hepatocellular carcinoma, lung and bladder cancers, osteosarcoma, rhabdomyosarcoma).
- Authors recommend further investigation, particularly combining isoflavones with established chemotherapeutics, to evaluate potential synergy.
Limitations: This article is a narrative review and does not present new clinical trial data.; The evidence summarized is primarily preclinical (in vitro and in vivo) with no clinical trial data provided in the abstract.; Mechanistic proposals are not proven clinical effects and require further experimental and clinical validation.; Safety and efficacy in patients, optimal dosing, and interactions with standard therapies are not established in this review..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewInconclusiveLimited evidenceTier 4 · clinical
The Urologic clinics of North America · May 2026
prostate adenocarcinomaprostate cancer
This review summarizes modern radiotherapy approaches for patients with high-risk or very-high-risk prostate adenocarcinoma, noting shorter courses, selectively higher radiation doses, and elective pelvic nodal irradiation. It also discusses combining radiotherapy with intensification of androgen-deprivation therapy and active studies using genomic risk stratification to guide treatment intensification or deintensification.
Studied with: androgen-deprivation therapy.
Key findings
- Modern radiotherapy strategies include fewer treatments (shorter courses).
- Approaches permit selectively higher radiation doses.
- Elective pelvic nodal treatment is used in some modern strategies.
- There is potential to intensify androgen-deprivation therapy alongside radiotherapy.
- Active studies are evaluating tailoring radiotherapy and androgen-deprivation based on genomic risk stratification tools.
Limitations: Narrative review without primary data reported in the abstract.; Abstract provides no quantitative outcomes, effect sizes, or specific trial results.; Very brief abstract; details on methods, evidence quality, or recommendations are not provided..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewReported positiveLimited evidenceTier 4 · clinical
The Urologic clinics of North America · May 2026 · review
prostate adenocarcinomaclinical N1 prostate cancer (lymph node positive)
Clinical N1 prostate cancer means prostate adenocarcinoma with regional lymph node metastases identified before definitive therapy. The abstract emphasizes thorough diagnostic imaging to distinguish regional nodal disease from distant metastases. It states that multimodal therapy—typically combinations of surgery, radiation, and hormone (androgen deprivation) therapy—is the mainstay of management and that treatment should be individualized.
Studied with: surgery, radiation therapy, hormone therapy / androgen deprivation therapy.
Key findings
- Clinical lymph node positive prostate cancer is prostate adenocarcinoma with metastasis to regional lymph nodes detected prior to definitive therapy.
- This is an aggressive cancer with varying presentations and prognosis.
- Thorough diagnostic imaging is key to establishing this stage and distinguishing it from distant metastatic disease.
- The mainstay of therapy is multimodal treatment, typically surgery + radiation + hormone therapy or radiation therapy + hormone therapy.
- Both surgery- and radiation-based strategies can be effective when appropriately combined with androgen deprivation therapy; treatment individualization is important.
Limitations: Review article without primary new patient-level data reported in the abstract.; No quantitative outcomes, effect sizes, or sample sizes are provided in the abstract.; No details on specific agents, doses, timing, or selection criteria for surgery versus radiation are provided.; Heterogeneity of presentations and prognosis is noted but not stratified or quantified in the abstract..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Human · observationalSupportive careMixed resultsModerate evidenceTier 3 · early humann = 267586
Journal of the National Cancer Institute · Aug 2025 · prospective cohort study
Supportive carecervical cancerHodgkin lymphomaprostate cancerbreast cancercolorectal cancerlung cancerendometrial canceroral cavity and pharynx cancerkidney cancerovarian cancersarcomamelanomaleukemia
Researchers followed participants in three large prospective cohorts for up to 36 years to examine whether a cancer diagnosis was associated with later atherosclerotic cardiovascular disease (ASCVD). They documented 4,334 new ASCVD events among 49,603 incident cancer cases and found that cervical cancer and Hodgkin lymphoma were associated with higher ASCVD risk, prostate cancer with slightly lower risk, and that ASCVD risk trajectories over time varied by cancer type (for example, breast cancer survivors had lower ASCVD risk for the first 7.5 years, then risk increased).
Reported effects: new-onset ASCVD events among incident cancer cases 4334, n=49603 · cervical cancer HR 1.56 [1.06–2.29] · +6 more
Key findings
- During up to 36 years of follow-up, 4,334 new-onset ASCVD events among 49,603 incident cancer cases were documented.
- Cervical cancer was associated with increased ASCVD incidence (HR = 1.56, 95% CI = 1.06 to 2.29).
- Hodgkin lymphoma was associated with increased ASCVD incidence (HR = 2.80, 95% CI = 1.89 to 4.15).
- Prostate cancer was associated with lower ASCVD incidence (HR = 0.91, 95% CI = 0.85 to 0.97).
- Breast cancer survivors experienced lower ASCVD risk during the first 7.5 years after diagnosis, but risk gradually increased afterward (Pnonlinearity = .01).
- ASCVD risk increased over time among patients with cancers of the colorectum (P = .003), lung (P = .002), and endometrium (P = .04).
- No statistically significant association with ASCVD risk was observed for cancers of the oral cavity and pharynx, kidney, or ovary; sarcoma; melanoma; or leukemia.
Limitations: Observational cohort design cannot establish causality.; Potential for residual confounding despite multivariable adjustment.; Cohorts consist of nurses and health professionals, which may limit generalizability to other populations.; Abstract does not report details on cancer stage or treatments, which could influence ASCVD risk..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Case reportMechanismReported positiveLimited evidenceTier 3 · early humann = 1
NPJ precision oncology · Jul 2025 · Serial plasma epigenomic (circulating chromatin) profiling from a single patient case report
prostate adenocarcinomametastatic prostate cancer
The authors performed serial plasma circulating chromatin (epigenomic) profiling in a single patient with metastatic prostate cancer who developed squamous transformation. They detected dynamic changes in gene regulation in circulating chromatin that reflected emergence of squamous differentiation, enabling non-invasive diagnosis and monitoring of this resistance phenotype. The abstract notes potential therapeutic implications but provides no validation data.
Key findings
- Circulating chromatin (plasma epigenome) showed dynamic changes corresponding to squamous differentiation in a patient with metastatic prostate cancer.
- These plasma epigenomic changes enabled non-invasive detection and monitoring of treatment-emergent squamous transformation.
- Authors state the findings have potential therapeutic implications.
Limitations: Single-patient case report (n=1), limiting generalizability.; No validation cohort or independent replication reported in the abstract.; No quantitative results or performance metrics provided in the abstract.; Observational profiling; cannot establish clinical utility or impact on outcomes from the data presented..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text